Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.^{1, 2} Here, we report updated longer-term safety data of secukinumab exposure from PSO and PsA studies.

Methods: The PSO data pool consisted of 9 Phase III studies in moderate-to-severe plaque PSO and PsA pool consisted of 3 Phase III studies in active PsA. Secukinumab doses differed in the studies and included intravenous (up to 10 mg/kg) or subcutaneous (s.c.; 75–300 mg) loading, followed by s.c. maintenance dosing (300, 150 or 75 mg). Placebo patients were re-randomized to secukinumab at 12–24 weeks depending on study design. Exposure adjusted incident rates (EAIR) were used to adjust for differences in treatment exposure and analyses included all patients who received ≥1 dose of secukinumab.

Results: A total of 3893 and 1380 patients from PSO and PsA studies representing an exposure of 7769.0 and 2841.3 patient years, respectively, were included in this pooled safety analysis. In both PsO and PsA, the most frequently reported adverse events (AEs) with secukinumab were nasopharyngitis, headache, non-serious infections of the upper respiratory tract and arthralgia (Table). The EAIRs of AEs of special interest with secukinumab including serious infections, Candida infections, inflammatory bowel disease, and major adverse cardiac events (Table) were similar in both PSO and PsA indications, and comparable to those reported previously.^1,2 No cases of tuberculosis were reported.

Conclusion: Secukinumab demonstrated a favorable safety profile during long term treatment (up to 7769 patient-years of exposure) in patients with moderate-to-severe plaque PSO or PsA consistent with previous reports. Safety was comparable across psoriasis and PsA patients supporting long-term use in these chronic conditions.

References: 1. Van de Kerkhof PC, et al. J Am Acad Dermatol. 2016;75:83–98; 2. Mease PJ, et al. Arthritis Rheumatol. 201567:A2886.